Saffar Mansoor1, Ashish Sharma1,2, Javier Cáceres-Del-Carpio1, Leandro C Zacharias1,3, A Jayaprakash Patil4, Navin Gupta1, G Astrid Limb5, M Cristina Kenney1,5, Baruch D Kuppermann1. 1. Gavin Herbert Eye Institute, School of Medicine, University of California, Irvine, California, USA. 2. Department of Ophthalmology, Lotus Eye Care Hospital, Coimbatore, TN, India. 3. Serviço de Oftalmologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. 4. Department of Ophthalmology, University Hospitals of Morecambe Bay NHS Foundation Trust, Kendal, LA9 5JE, UK. 5. Department of Paediatric Ophthalmology, University Hospitals of Morecambe Bay NHS Foundation Trust, Kendal, LA9 5JE, UK.
Abstract
BACKGROUND: The aim of this study is to evaluate the safety profile of Brilliant Blue G (BBG) with and without exposure to light (L) on three different retinal cell lines. METHOD: ARPE-19, R28 and MIO-M1 cells were treated with BBG: 0.125 mg/mL (0.5x clinical concentration), 0.25 mg/mL (1x) or 0.5 mg/mL (2x) with or without surgical illumination of halogen light exposure for 10 min, 15 min or 30 min. Cells were further cultured after 24 h and then analysed for cell viability, late stages of apoptosis and mitochondrial damage associated with early apoptosis using assays that measure trypan blue dye exclusion, increases in caspase-3/7 activity or changes in mitochondrial membrane potential (ΔΨm), respectively. RESULT: All three cell lines that were exposed to BBG in the presence or absence of light exposure for 30 min were found to have cell viability and caspase-3/7 activity levels similar to the untreated cultures. The mitochondrial membrane potential (ΔΨm) was decreased significantly at the 2x + L dose and 2x dose in all three retinal cell lines compared to their respective untreated control cells. At the lower doses of BBG, with or without exposure to light, the ΔΨm values were similar to the untreated control cultures. CONCLUSION: Exposure to BBG dye concentrations that are used clinically (0.125 mg/mL and 0.25 mg/mL) in the presence up to 30 min of surgically equivalent light intensity is safe for retinal cells.
BACKGROUND: The aim of this study is to evaluate the safety profile of Brilliant Blue G (BBG) with and without exposure to light (L) on three different retinal cell lines. METHOD: ARPE-19, R28 and MIO-M1 cells were treated with BBG: 0.125 mg/mL (0.5x clinical concentration), 0.25 mg/mL (1x) or 0.5 mg/mL (2x) with or without surgical illumination of halogen light exposure for 10 min, 15 min or 30 min. Cells were further cultured after 24 h and then analysed for cell viability, late stages of apoptosis and mitochondrial damage associated with early apoptosis using assays that measure trypan blue dye exclusion, increases in caspase-3/7 activity or changes in mitochondrial membrane potential (ΔΨm), respectively. RESULT: All three cell lines that were exposed to BBG in the presence or absence of light exposure for 30 min were found to have cell viability and caspase-3/7 activity levels similar to the untreated cultures. The mitochondrial membrane potential (ΔΨm) was decreased significantly at the 2x + L dose and 2x dose in all three retinal cell lines compared to their respective untreated control cells. At the lower doses of BBG, with or without exposure to light, the ΔΨm values were similar to the untreated control cultures. CONCLUSION: Exposure to BBG dye concentrations that are used clinically (0.125 mg/mL and 0.25 mg/mL) in the presence up to 30 min of surgically equivalent light intensity is safe for retinal cells.
Authors: Sebastian Mueller; Carlo Krupp; Sven Schnichels; Johanna Hofmann; Martin Spitzer; Karl Ulrich Bartz-Schmidt; Peter Szurman; Kai Januschowski Journal: Graefes Arch Clin Exp Ophthalmol Date: 2019-02-20 Impact factor: 3.117